ADMA Biologics: Investor Deadline Set for Class Action Lawsuit
Investors who purchased ADMA Biologics securities and suffered losses have until August 10, 2026, to seek to lead a class action lawsuit.
Purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024, and March 25, 2026, who have experienced substantial losses, have an opportunity to lead a class action lawsuit. The deadline for investors to file their claims is Monday, August 10, 2026, according to the law firm Robbins Geller Rudman & Dowd LLP.
The lawsuit alleges violations of federal securities laws by ADMA Biologics and certain of its officers and directors. The securities litigation aims to recover damages for investors who were harmed by alleged misrepresentations or omissions during the specified class period.
Robbins Geller Rudman & Dowd LLP is encouraging eligible investors to contact the firm to learn more about the litigation and their rights. The firm is investigating the claims and assessing the potential merits of the case on behalf of affected shareholders.
This legal action could have implications for the company's future operations and stock performance. Further details regarding the lawsuit and eligibility criteria are available through the law firm's announcement.